The Board

Introduction to the IML team, our Board of Directors and the experts and members of our various working groups with whom we collaborate.

The Board of Directors sets IML's strategic priorities, its key objectives and approves IML's policy positions, thus ensuring good governance and alignment of IML's public policies in a local context.

Team

Board

Task force and experts

Arnaud Loriers

Head Grand Duchy of Luxembourg - Novartis

Ann Vanden Wyngaerd

Market Access Manager - Sanofi

Marilyn Coppenrath

Head Market Access & Public Affairs - Boehringer Ingelheim

Sébastien Massart

Director Market Access, Pricing and Governmental Affairs - Merck

Marie-Lise Verschelden

Senior Manager Communication - Pfizer

Elke De Blay

Communication Manager - Novartis

Pieter-Jan Mattheus

Governmental Affairs and Policy Manager - Bristol-Myers Squibb

Rudy De Cock

Director Health & Value - Pfizer

Barbara Merckx

Policy Manager Vaccines and Infectious Diseases - MSD

Charline Desmecht

Corporate Affairs Lead - UCB

Julien Patris

Director Market Access & Policy - Alnylam Pharmaceuticals

Marie-Charlotte Destree

Legal advisor - pharma.be

Christine Petit

Head of Public Affairs & Market Access

David Gering

Communication Director - pharma.be

Koen Raeymaekers

Medical liaison in oncology/hematology - AMGEN

Birce Suntay

Senior Market Access Manager - BMS

Robert Henkinet

External Relations Lead - Janssen-Cilag

Mia Rasmussen

Ethics & Compliance - UCB

Karen Crabbé

Economist and health data policy expert

Bettina Schroeders

Director of Regulatory Affairs - Merck

Nathalie Lambot

Expert Public Health: Clinical Trials-Regulatory Affairs - pharma.be

Frédéric Septon

Development partner in neurology and head of the ecosystem CNS BeLux - UCB

Muriel L'Heureux

Patient Journey Partner Neurosciences - Roche

Davy T’Jampens

Head of Patient Value & Access - Takeda
Become a member

Interested in becoming a partner?

To benefit from all of our services, more particularly :

  • Participate in committees and commissions, in the different working groups
  • Free access to our intranet
  • Profit of the organizations networh:  exchangres between experts, invitation to formations and exclusive meetings (economical, scientific, industrial, social, legal, RSE, parlementary, european, communication…)
  • Being represented and being defended in front of institutions and the public, see the image of drug producing companies valued.

for more detailed information about the adhesion steps, please, contact us by mail contact@iml.lu .